Quick Answer
Vaxcyte, Inc. reported Operating Income of -$923.67 million for fiscal year 2025.
Vaxcyte, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$923.67M | -62.2% |
| 2024 | -$569.55M | -21.7% |
| 2023 | -$468.04M | -101.5% |
| 2022 | -$232.26M | -124.0% |
| 2021 | -$103.67M | -15.7% |
| 2020 | -$89.58M | -65.4% |
| 2019 | -$54.15M | -52.4% |
| 2018 | -$35.53M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$242.38M | -73.2% | -7.1% |
| June 30, 2025 | -$226.22M | -47.9% | -25.1% |
| March 31, 2025 | -$180.79M | -57.9% | -29.2% |
| September 30, 2024 | -$139.92M | -23.8% | +8.5% |
| June 30, 2024 | -$152.98M | -75.5% | -33.6% |
| March 31, 2024 | -$114.47M | -60.8% | -1.3% |
| September 30, 2023 | -$113.03M | -93.0% | -29.7% |
| June 30, 2023 | -$87.15M | -82.0% | -22.4% |
- Vaxcyte, Inc. showed a decrease of -62.2% in Operating Income compared to the prior fiscal year.
- Over the 2018–2025 period, Vaxcyte, Inc.’s operating income has declined by 2499.5% (from -$35.53 million to -$923.67 million).
- The most recent figure is from Vaxcyte, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: